Pier Luigi Zinzani
Pier Luigi Zinzani
Email verificata su
Citata da
Citata da
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial byá…
M Pfreundschuh, L TrŘmper, A Ísterborg, R Pettengell, M Trneny, K Imrie, ...
The lancet oncology 7 (5), 379-391, 2006
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ...
The Lancet 376 (9747), 1164-1174, 2010
Follicular lymphoma international prognostic index
P Solal-CÚligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ...
Blood 104 (5), 1258-1265, 2004
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma
R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ...
Journal of Clinical Oncology 35 (19), 2125, 2017
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of theá…
M Pfreundschuh, E Kuhnt, L TrŘmper, A Ísterborg, M Trneny, L Shepherd, ...
The lancet oncology 12 (11), 1013-1022, 2011
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
W Au, DD Weisenburger, T Intragumtornchai, S Nakamura, WS Kim, I Sng, ...
Blood, The Journal of the American Society of Hematology 113 (17), 3931-3937, 2009
ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
B Falini, S Pileri, PL Zinzani, A Carbone, V Zagonel, C Wolf-Peeters, ...
Blood, The Journal of the American Society of Hematology 93 (8), 2697-2706, 1999
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
SA Pileri, S Ascani, MC Cox, C Campidelli, F Bacci, M Piccioli, ...
Leukemia 21 (2), 340-350, 2007
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma
JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ...
New England Journal of Medicine 378 (4), 331-344, 2018
Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure
P Armand, MA Shipp, V Ribrag, JM Michot, PL Zinzani, J Kuruvilla, ...
Journal of Clinical Oncology 34 (31), 3733, 2016
Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-armá…
P Armand, A Engert, A Younes, M Fanale, A Santoro, PL Zinzani, ...
Journal of Clinical Oncology 36 (14), 1428, 2018
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, ...
Journal of Clinical Oncology 29 (9), 1182, 2011
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ...
Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
E Zucca, A Conconi, E Pedrinis, S Cortelazzo, T Motta, ...
Blood, The Journal of the American Society of Hematology 101 (7), 2489-2495, 2003
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ...
The Lancet 390 (10094), 555-566, 2017
T (11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication
H Liu, H Ye, A Ruskone–Fourmestraux, D De Jong, S Pileri, C Thiede, ...
Gastroenterology 122 (5), 1286-1294, 2002
Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ...
Journal of Clinical Oncology 26 (32), 5156-5164, 2008
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20